CCDC62

Across TCGA pan-cancer cohorts, CCDC62 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCDC62 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CCDC62 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CCDC62 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, GBM, and LUAD are the cancer types where CCDC62 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	1.000	0.695	.007	13	view →
GBM	DFS	Median	All	0.406	0.763	.002	8	view →
LUAD	OS	Median	II,III,IV	0.356	0.893	.025	6	view →
CCRCC	DFS	Median	IV	0.222	0.887	.038	3	view →
LSCC	DFS	Tertile	All	0.921	1.000	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCDC62–HNSC (DFS)

Open the HNSC breakdown →